Stay updated on Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The study record for a phase I/II trial of carboplatin, nab-paclitaxel, and pembrolizumab in advanced non-small cell lung cancer is available, including its design, eligibility criteria, outcomes, and results. It also indicates that the trial was terminated after being fully accrued and is no longer recruiting.
    Difference
    68%
    Check dated 2026-11-07T14:36:21.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now shows revision v3.8.0 instead of v3.7.2. The page still displays a 403 Forbidden error rather than the study record.
    Difference
    0.2%
    Check dated 2026-10-31T15:36:41.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T19:28:02.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.1 to v3.7.2; the page still displays a 403 error.
    Difference
    0.2%
    Check dated 2026-10-17T19:39:39.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1; the page remains a 403 Forbidden error rather than a clinical trial record.
    Difference
    0.2%
    Check dated 2026-10-10T20:19:06.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden error, replacing the study details with a minimal error page and a site footer.
    Difference
    21%
    Check dated 2026-09-19T19:12:26.000Z thumbnail image

Stay in the know with updates to Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.